Hyaluronic acid-modified PLGA nanoparticles for enhanced ocular drug delivery
AIM: To develop hyaluronic acid (HA)-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles (HA-PLGA NPs) for enhanced triamcinolone acetonide (TA) ocular delivery. METHODS: pharmacokinetics in rabbit aqueous humour were evaluated. RESULTS: ·min) compared to unmodified nanoparticles. CONCLUSIONS: HA-PLGA NPs provide a high-efficiency, non-invasive platform for treating posterior segment diseases by overcoming ocular barriers through bioadhesion.
Authors
- Huanhuan Jia (ORCID: https://orcid.org/0000-0003-4151-0915)
- Junfeng Ban (ORCID: https://orcid.org/0000-0001-7334-9375)
- Fan Li (ORCID: https://orcid.org/0000-0003-2584-3162)
- Huashen He
- Bisen Su
- Sa Huang
- Tianyu Tang
- Shuguang Li
- Hui Chen
Institutions
- Guilin Medical University (CN)
- Guangdong Pharmaceutical University (CN)
- The Medical Device (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Microencapsulation
- Published
- 2026-05-21
- DOI
- https://doi.org/10.1080/02652048.2026.2669806
- Primary Topic
- Advanced Drug Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Middle-aged and Young Teachers' Basic Ability Promotion Project of Guangxi